Biomarkers · 2018 · 18 citations · 24 references
MedicineMolecular MedicineOncologyGene ExpressionGene Expression AnalysisMolecular OncologyBreast Cancer RecurrenceCancer BiomarkersCancer Survival AnalysisCancer TranscriptomicsMicrorna BiologyNoncoding Rna In CancerBreast Cancer PrognosisHormone Receptor - Positive Breast CancerMicrorna BiomarkersMicrorna Expression ProfilingMicrorna In CancerMicrorna Prognostic MarkersReal-time Polymerase Chain Reaction (Pcr)Recurrence
PURPOSE: To identify miRNAs associated with distant recurrence during tamoxifen treatment and build a recurrence prediction model. MATERIALS AND METHODS: We measured the expression of five miRNAs (miR-134, miR-125b-5P, miRNA-30a, miR-10a-5p and miR-222). A total of 176 tumour tissues from 176 patients who had hormone receptor positive breast cancer with tamoxifen treatment were used to measure miRNA expression using quantitative real-time PCR (qRT-PCR). RESULTS: The five miRNAs were all up-regulated in distant recurrence cases within 5 years after surgery and during tamoxifen treatment. Kaplan-Meier survival analyses based on expression cut-offs determined by receiver characteristics curves (ROC) showed that high expression of miR-134, miR-125b-5P, miRNA-30a, miR-10a-5p and miR-222 were significantly (log-rank p-value =0.006, p-value <0.0001, p-value <0.0001, p-value <0.0001 and p-value <0.0001, respectively) associated with short relapse-free time. Our results were used to build a combined 3 miRNAs expression model. It could be used to categorize high-risk subset of patients with short relapse-free survival (AUC =0.891, p-value <0.0001). CONCLUSIONS: Distant recurrence during tamoxifen treatment of hormone positive breast cancer might be affected by tamoxifen resistance related miRNAs. Such distant recurrence can be predicted using miRNA measurement.
24
Aron Goldhirsch, Eric P. Winer, Alan S. Coates et al. · Annals of Oncology · 2013 · 3.7K citations · Full text
Medicine, Oncology, Breast Oncology +10